Dublin, Ireland, 31 May 2022: The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups,…
Sumitomo Pharma takes license to CRISPR/Cas9 patent portfolio from ERS Genomics Dublin, Ireland, 26 April 2022: ERS Genomics Limited (‘ERS’) is pleased to confirm finalization…
Dublin, Ireland, 7 April 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a license agreement with Central Institute for Experimental Animals (“CIEA”) in Japan.…
CVC maintains strong US patent portfolio covering CRISPR/Cas9 despite PTAB ruling Dublin/Ireland, March 1, 2022: ERS Genomics announced today that the U.S. Patent and Trademark…
ERS Genomics team expands with new hire, Ralph Vogelsang Dr. Ralph Vogelsang joins as Senior Director for Business Development & Licensing, EMEA Dublin, Ireland,…
China’s gene-editing landscape advances as CVC’s second CRISPR/Cas9 patent granted New patent covers methods and compositions for use of CRISPR/Cas9 in eukaryotes. Dublin, Ireland,…
ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models…
License agreement to enhance Nippon Gene’s CRISPR/Cas9 research reagents offering Dublin, Ireland and Tokyo, Japan, 01 July 2021: ERS Genomics Limited, which was formed to…
Dublin, Ireland and Lyon, France, 07 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned…